PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease

Neuroscience Letters

Volumn 408, Issue 1, 2006, Pages 57-61

  Holzapfel, Julia ^a   Heun, Reinhard ^a   Lütjohann, Dieter ^a   Jessen, Frank ^a   Maier, Wolfgang ^a   Kölsch, Heike ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; Association; Cholesterol; Peroxisome proliferator activated receptor delta; Polymorphism

Indexed keywords

26 HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; EXON; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RECEPTOR GENE; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLESTEROL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR DELTA; RISK FACTORS;

EID: 33749074664     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.08.029     Document Type: Article

References (22)

1. Becker T., and Knapp M. A powerful strategy to account for multiple testing in the context of haplotype analysis. Am. J. Hum. Genet. 75 (2004) 561-570
2. Blacker D., Bertram L., Saunders A.J., Moscarillo T.J., Albert M.S., Wiener H., Perry R.T., Collins J.S., Harrell L.E., Go R.C.P., Mahoney A., Beaty T., Fallin M.D., Avramopoulos D., Chase G.A., Folstein M.F., McInnis M.G., Bassett S.S., Doheny K.J., Pugh E.W., and Tanzi R.E. Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Hum. Mol. Genet. 12 (2003) 23-32
3. Bretillon L., Lütjohann D., Stahle L., Widhe T., Bindl L., Eggertsen G., Diczfalusy U., and Björkhem I. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J. Lipid Res. 41 (2000) 840-845
4. Brune S., Kölsch H., Ptok U., Schulz A., Schlosser R., Rao M.L., Maier W., and Heun R. Polymorphism in the peroxisome proliferators-activated receptor gene increases the risk for Alzheimer's disease by interaction with insulin gene polymorphism. J. Neural Transm. 110 (2003) 1041-1050
5. Chen S., Tsybouleva N., Ballantyne C.M., Gotto Jr. A.M., and Marian A.J. Effects of PPAR α, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 14 (2004) 61-71
6. Dzeletovic S., Breuer O., Lund E., and Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal. Biochem. 225 (1995) 73-80
7. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
8. Grundy S.M. Cholesterol and coronary heart disease. The 21st century. Arch. Intern. Med. 158 (1998) 1156-1158
9. Hamajima N., Saito T., Matsuo K., Kozaki K., Takahashi T., and Tajima K. Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping. Jpn. J. Cancer Res. 91 (2000) 865-868
10. Hiltunen M., Mannermaa A., Thompson D., Easton D., Pirskanen M., Helisalmi S., Koivisto A.M., Lehtorvirta M., Ryynanen M., and Soininen H. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology 57 (2001) 1663-1668
11. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
12. Kölsch H., Heun R., Kerksiek A., von Bergmann K., Maier W., and Lütjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Nerosci. Lett. 368 (2004) 303-308
13. Koudinov A.R., and Koudinov N.V. Cholesterol, synaptic function and Alzheimer's disease. Pharmacopsychiatry 36 (2003) 107-112
14. Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Knowles H., Morris J.C., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., Rice F., Giles P., Tunstall N., Jones L., Lovestone S., Williams J., Owen M.J., Hardy J., and Goate A. Full genome screen for Alzheimer's disease: stage II analysis. Am. J. Med. Genet. 114 (2002) 235-244
15. Notkola I.L., Sulkava R., Pekkanen J., Erkinjuntti T., Ehnholm C., Kivinen P., Tuomilehto J., and Nissinen A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 17 (1998) 14-20
16. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5306-5311
17. Sauder S., Kölsch H., Lütjohann D., Schulz A., Bergmann K.V., Maier W., and Heun R. Influence of peroxisome proliferator-activated receptor γ gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's disease. J. Neural Transm. 112 (2005) 1381-1389
18. Skogsberg J., Kannisto K., Cassel T.N., Hamsten A., Eriksson P., and Ehrenborg E. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 637-643
19. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 1977-1981
20. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., and Sakai J. Activation of peroxisome proliferator-activated receptor δ induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15924-15929
21. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
22. Yoshikawa T., Brkanac Z., Dupont B.R., Xing G.Q., Leach R.J., and Detera-Wadleigh S.D. Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2. Genomics 35 (1996) 637-638